Streetbeat News

Earnings

AQST

Aquestive Therapeutics (NASDAQ:AQST) is scheduled to release its quarterly earnings report on March 5, 2024, with an expected EPS of $-0.08. The company's past earnings performance shows a mixed pattern of beating and missing EPS estimates, leading to varying stock price reactions. Shares have significantly appreciated over the last year, with a 382.35% increase. Investors are particularly focused on the company's guidance for future growth.

Portfolio Pulse from Benzinga Insights

March 04, 2024 | 5:02 pm

SOPH

Sophia Genetics (NASDAQ:SOPH) is scheduled to release its quarterly earnings report on March 5, 2024, with an expected EPS of $-0.26. Analysts and investors are keen on whether the company will surpass this estimate and provide positive guidance for the next quarter. Despite beating the EPS estimate last quarter, SOPH's share price did not increase the following day. Historically, the company's earnings performance has shown mixed results on its stock price. Currently, SOPH shares are trading at $4.84, reflecting a 99.6% increase over the last 52 weeks, indicating a positive sentiment among long-term shareholders.

Portfolio Pulse from Benzinga Insights

March 04, 2024 | 5:02 pm

CGEN

Compugen (NASDAQ:CGEN) is scheduled to release its quarterly earnings report on 2024-03-05, with analysts expecting an EPS of $0.22. The company's past earnings performance shows a mix of misses and beats, with the stock price reacting accordingly. Shares have risen 243.79% over the last 52 weeks, indicating a positive long-term outlook. Investors will be keen on both the earnings outcome and the company's guidance for future growth.

Portfolio Pulse from Benzinga Insights

March 04, 2024 | 5:01 pm

CXDO

Crexendo (NASDAQ:CXDO) is scheduled to release its quarterly earnings report on March 5, 2024, with an expected EPS of $0.04. Historically, the company has surpassed EPS estimates, leading to significant stock price movements. Last quarter, Crexendo beat the EPS estimate by $0.10, resulting in a 9.71% share price increase the following day. Over the past year, CXDO shares have surged by 196.13%, indicating strong investor confidence ahead of the upcoming earnings announcement.

Portfolio Pulse from Benzinga Insights

March 04, 2024 | 5:01 pm

AEVA

Aeva Technologies (NYSE:AEVA) is expected to report a Q4 earnings per share (EPS) of $-0.15 on March 5, 2024. Historically, the company has beaten EPS estimates but experienced share price drops post-earnings. Over the last year, AEVA shares have declined by 38.61%, with the stock currently trading at $1.03. Investors are looking for not just an earnings beat but also positive guidance for future growth.

Portfolio Pulse from Benzinga Insights

March 04, 2024 | 5:01 pm

LXU

LSB Industries (NYSE:LXU) is scheduled to release its quarterly earnings report on 2024-03-05, with analysts estimating an EPS of $0.04. The company's past earnings performance shows mixed results, with the last quarter beating estimates by $0.02 but resulting in a 2.18% share price drop the following day. Over the last year, LXU shares have declined by 44.91%, indicating potential investor concern ahead of the earnings announcement.

Portfolio Pulse from Benzinga Insights

March 04, 2024 | 5:01 pm

FLL

Full House Resorts (NASDAQ:FLL) is scheduled to release its quarterly earnings report on March 5, 2024, with an estimated EPS of $-0.14. Historical data shows a pattern of stock price movement post-earnings announcement, with a notable 18.67% increase after last quarter's beat. Over the past year, FLL shares have declined by 47.63%, indicating a bearish sentiment among long-term shareholders.

Portfolio Pulse from Benzinga Insights

March 04, 2024 | 5:01 pm

NPCE

NeuroPace (NASDAQ:NPCE) is scheduled to release its quarterly earnings report on 2024-03-05, with analysts expecting an EPS of $-0.31. The company's past performance shows a mixed reaction to earnings reports, with the last quarter beating estimates but resulting in a 1.81% drop in share price the next day. Shares have risen 250.34% over the last 52 weeks, indicating a positive long-term outlook among shareholders.

Portfolio Pulse from Benzinga Insights

March 04, 2024 | 5:01 pm

TGT

Target (NYSE:TGT) is anticipated to release its quarterly earnings report on Tuesday, with analysts expecting an EPS of $2.41. Investors are hopeful for a beat on this estimate and positive guidance for the next quarter. Target's past earnings performance shows a mix of beats and misses, with the share price reacting variably. Currently, shares are trading at $155.29, down 7.08% over the last 52 weeks, indicating potential concern among long-term shareholders ahead of the earnings release.

Portfolio Pulse from Benzinga Insights

March 04, 2024 | 5:00 pm

BCDA

BioCardia shares are trading lower due to volatility following the announcement of interim results from its Phase III CardiAMP cell therapy heart failure trial.

Portfolio Pulse from Benzinga Newsdesk

March 04, 2024 | 4:45 pm